547 related articles for article (PubMed ID: 22491949)
1. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Hrkach J; Von Hoff D; Mukkaram Ali M; Andrianova E; Auer J; Campbell T; De Witt D; Figa M; Figueiredo M; Horhota A; Low S; McDonnell K; Peeke E; Retnarajan B; Sabnis A; Schnipper E; Song JJ; Song YH; Summa J; Tompsett D; Troiano G; Van Geen Hoven T; Wright J; LoRusso P; Kantoff PW; Bander NH; Sweeney C; Farokhzad OC; Langer R; Zale S
Sci Transl Med; 2012 Apr; 4(128):128ra39. PubMed ID: 22491949
[TBL] [Abstract][Full Text] [Related]
2. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy.
Werner ME; Copp JA; Karve S; Cummings ND; Sukumar R; Li C; Napier ME; Chen RC; Cox AD; Wang AZ
ACS Nano; 2011 Nov; 5(11):8990-8. PubMed ID: 22011071
[TBL] [Abstract][Full Text] [Related]
3. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
[TBL] [Abstract][Full Text] [Related]
5. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Farokhzad OC; Cheng J; Teply BA; Sherifi I; Jon S; Kantoff PW; Richie JP; Langer R
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6315-20. PubMed ID: 16606824
[TBL] [Abstract][Full Text] [Related]
7. Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles.
Au KM; Min Y; Tian X; Zhang L; Perello V; Caster JM; Wang AZ
ACS Nano; 2015 Sep; 9(9):8976-96. PubMed ID: 26267360
[TBL] [Abstract][Full Text] [Related]
8. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
[TBL] [Abstract][Full Text] [Related]
9. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
10.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy.
Chu KS; Schorzman AN; Finniss MC; Bowerman CJ; Peng L; Luft JC; Madden AJ; Wang AZ; Zamboni WC; DeSimone JM
Biomaterials; 2013 Nov; 34(33):8424-9. PubMed ID: 23899444
[TBL] [Abstract][Full Text] [Related]
12. Boosting the therapeutic efficacy of discoidal nanoconstructs against glioblastoma with rationally designed PEG-Docetaxel conjugates.
Felici A; Schlich M; Di Mascolo D; Goldoni L; Lisa Palange A; Decuzzi P
Eur J Pharm Biopharm; 2022 May; 174():90-100. PubMed ID: 35358697
[TBL] [Abstract][Full Text] [Related]
13. Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.
Liu J; Kopečková P; Pan H; Sima M; Bühler P; Wolf P; Elsässer-Beile U; Kopeček J
Macromol Biosci; 2012 Mar; 12(3):412-22. PubMed ID: 22493797
[TBL] [Abstract][Full Text] [Related]
14. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
15. Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO 2014210485A1).
Pooja D; Kulhari H; Adams DJ; Sistla R
Expert Opin Ther Pat; 2016 Jul; 26(7):745-9. PubMed ID: 27088623
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficiency of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer.
Wang Z; Zeng X; Ma Y; Liu J; Tang X; Gao Y; Liu K; Zhang J; Ming P; Huang L; Mei L
J Biomed Nanotechnol; 2014 Aug; 10(8):1509-19. PubMed ID: 25016651
[TBL] [Abstract][Full Text] [Related]
17. Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo.
Feng L; Wu H; Ma P; Mumper RJ; Benhabbour SR
Int J Nanomedicine; 2011; 6():2545-56. PubMed ID: 22072889
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
20. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
